#United States #New York #Class Action #Rosen Law Firm #Replimune Group

Investors Alert: Replimune Group, Inc. Securities Lawsuit

For those who invested in Replimune Group, Inc. (NASDAQ: REPL), significant news is on the horizon. The Rosen Law Firm, recognized for its robust advocacy for investor rights, has announced an important opportunity for those who experienced losses exceeding $100,000 during the Class Period from November 22, 2024, to July 21, 2025. The firm is urging affected investors to come forward to be potential lead plaintiffs in a securities class action lawsuit.

Important Dates

The first critical date to remember is September 22, 2025. On this day, the deadline to apply to serve as the lead plaintiff in the class action lawsuit will close. Being a lead plaintiff means taking on a representative role for other investors, which involves directing the litigation process. This is an essential step for those who believe they suffered losses due to misleading statements made by the company.

No Out-of-Pocket Fees

Investors may join the class action without needing to pay out-of-pocket fees or expenses upfront, as the firm operates on a contingency fee basis. This means that legal fees are only taken from any recovery amounts achieved in the lawsuit, making it financially easy for investors to seek redress.

Class Action Details

The lawsuit claims that during the Class Period, Replimune's management made materially false statements about the prospects of the IGNYTE trial. This included overstating its potential positively while neglecting key issues that could impact its effectiveness. Specifically, the U.S. Food and Drug Administration (FDA) had criticized the IGNYTE trial for not being adequately controlled, an aspect the defendants allegedly failed to disclose to their investors.

When these realities came to light, the lawsuit alleges that investors found themselves facing significant financial damage due to the misleading information circulated by the company.

Making a Move

Investors who purchased Replimune securities during the specified period are encouraged to take action. They can visit the Rosen Law Firm’s dedicated webpage or call directly for more information on how to join the class action. This lawsuit may represent an opportunity for many to recover their losses.

Selecting the Right Counsel

The Rosen Law Firm emphasizes the importance of choosing experienced legal representation. Many investment firms simply act as middlemen, referring clients to actual litigation firms without having significant experience in handling securities class actions. When seeking legal support, investors are advised to examine the track record of proposed counsel, as having a reputable and successful firm on your side can make all the difference in the outcome.

Class Status and Future Recovery

It’s vital to note that currently, no class has been certified. This means until a certification takes place, individual investors are not officially represented in this class action unless they choose to retain legal counsel independently. Even if they want to remain absentee class members, they are still eligible to share in any potential recoveries from the lawsuit.

Stay Updated

For ongoing information regarding this case and other pertinent updates about Replimune Group and its associated legal matters, investors can follow the Rosen Law Firm on various social media platforms or contact them through official channels.

Contact Information

For details on participation and case specifics, interested parties should contact:

• - Phillip Kim, Esq.
• - The Rosen Law Firm, P.A.
• - Email: [email protected]
• - Phone: 866-767-3653
• - Address: 275 Madison Avenue, 40th Floor, New York, NY 10016.

The Rosen Law Firm has successfully recovered substantial amounts for investors in past cases, having depicted an unwavering commitment to investor rights. If you're a Replimune investor affected by misleading information, consider acting quickly and securing your legal rights to potential compensation.